Novavax completed enrollment of PREVENT-19, COVID-19 vaccine pivotal phase 3 trial in the US and Mexico
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
-
-
Johnson & Johnson announces submission to WHO for EUL of investigational single-shot COVID-19 vaccine candidate
On Feb. 19, 2021, Johnson & Johnson announced that Janssen-Cilag had submitted for Emergency Use Listing (EUL) to…
-
World’s largest clinical trial for COVID-19 treatments expanded internationally
On Feb. 18, 2021, scientists at the University of Oxford announced that the Randomised Evaluation of COVID-19 Therapy…
-
Novavax announced MOU with Gavi for cumulative supply to COVAX facility of 11 billion doses of COVID-19 vaccine
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
-
Plans underway for pediatric COVID-19 vaccine trials
On Feb. 18, 2021, Washington University pediatric infectious diseases doctors announced plans to launch clinical trials in the…
-
Altimmune announced FDA clearance of AdCOVID IND application
On Feb. 17, 2021, Altimmune announced that the U.S. Food and Drug Administration (FDA) had cleared the Companyls…
-
Anixa Biosciences began animal Testing of Covid-19 therapeutic candidates
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
-
Johnson & Johnson announced submission of Marketing Authorisation Application to EMA for Janssen COVID-19 vaccine candidate
On Feb. 16, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, has submitted a conditional Marketing Authorisation…
-
Novavax announced expanded agreement with SK Bioscience for 40 million doses of COVID-19 vaccine for South Korea
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
-
DOD participated in COVID-19 antibody treatment trial
On Feb. 11, 2021, the the Military Health System (MHS) announced partcipation in the AstraZeneca phase III clinical…
-
Clinical trial in hospitalized COVID-19 patients evaluate long-acting antibody therapy
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
-
NanoViricides’s antiviral drug candidate for treatment of COVID-19 infections well tolerated in animal safety studies
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
-
Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
-
Johnson & Johnson announced submission of application to FDA for EUA of its single-shot COVID-19 vaccine candidate
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
-
AXIM Biotechnologies began clinical trials of ImmunoPass rapid diagnostic test with vaccine recipients
On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyﾒs rapid point-of-care test…
-
Dynavax and Serum Institute announced first participant dosed in trial evaluating Tdap vaccine adjuvanted with CpG 1018
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…
-
First-in-human clinical trial confirmed novel HIV vaccine approach
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
-
Rigel awarded $165 Million from US DOD for phase 3 clinical trial of Fostamatinib in COVID-19 patients
On Jan. 29, 2021, Rigel Pharma announced it has been awarded $16.5 million by the U.S. Department of…
-
Innovation Pharmaﾒs phase 2 clinical trial of Brilacidin for treating COVID-19 began
On Jan. 29, 2021, Innovation Pharmaceuticals announced that the companyﾒs Phase 2 clinical trial of Brilacidin for treating…
-
Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of phase 3 ENSEMBLE trial
On Jan. 29, 2021, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE…
-
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
-
OncoSec announced first subjects dosed in phase 1 trial of CORVax12, COVID-19 vaccine candidate
On Jan. 27, 2021, OncoSec Medical announced that it had dosed several subjects in its Phase 1 clinical…
-
Antibody infusions prevented acquisition of some HIV strains, NIH studies found
On Jan. 26, 2021, NIH researchers announced that an investigational anti-HIV antibody delivered intravenously once every eight weeks…
-
Regeneron reported positive data with REGEN-COV antibody cocktail as passive vaccine to prevent COVID-19
On Jan. 26, 2021, Regeneron announced positive initial results from an ongoing Phase 3 clinical trial evaluating REGEN-COV…
-
Medigen’s COVID-19 vaccine announced first participant dosed in phase 2 clinical trial in Taiwan
On Jan. 25, 2021, Medigen Vaccine Biologics and Dynavax Technologies announced that the first participant had been dosed…
-
Low-dose aspirin may improve pregnancy chances for women with one or two prior miscarriages
On Jan. 25, 2021, the National Institutes of Health (NIH) announced that in large clinical trial conducted worldwide,…
-
Full-dose blood thinners decreased need for life support and improved outcome in COVID-19 patients
On Jan. 22, 2021, the NIH announced that in large clinical trial conducted worldwide, full dose anti-coagulation (blood…
-
Moderna announced first participant dosed in phase 1/2 study of COVID-19 vaccine in Japan led by Takeda
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…
-
ImmunityBio announced phase I trial of COVID-19 vaccine candidate in South Africa as new variants spread
On Jan. 19, 2021, ImmunityBio announced it had received authorization from the South Africa Health Products Regulatory Authority…
-
RECOVERY trial closed recruitment to convalescent plasma treatment for patients hospitalised with COVID-19
On Jan. 15, 2021, Oxford University announced that on advice of the independent Data Monitoring Committee (DMC), recruitment…
